Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.
Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G.
Eur Urol. 2005 Apr;47(4):449-54; discussion 454-5. Epub 2005 Jan 19.
PMID: 15774240
doi:10.1016/j.eururo.2004.12.001
ScienceDaily (Mar. 10, 2009) - A study led by researchers at the University of Southern California (USC) found that men who took a daily folic acid supplement of 1 mg daily had more than twice the risk of prostate cancer compared with men who took a placebo.
When these cell cultures were treated with red clover isoflavones, the androgenic effects of DHEA were reversed.
"Something is happening in the prostate tissue microenvironment that is illustrating a potential cancer prevention effect from this supplement," said Arnold.
Red clover isoflavones may modify androgenic effects in the prostate but much more work in the laboratory and clinic is needed to validate these effects.
Flaig TW, Su LJ, Harrison G, Agarwal R, Glode LM.
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.
Int J Cancer. 2007 Jan 17; [Epub ahead of print]
PMID: 17230508 [PubMed - as supplied
Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM.
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
Invest New Drugs. 2007 Apr;25(2):139-46. Epub 2006 Nov 1.
PMID
Singh RP, Agarwal R.
Prostate cancer chemoprevention by silibinin: bench to bedside.
Mol Carcinog. 2006 Jun;45(6):436-42. Review.
PMID: 16637061 [PubMed - indexed for MEDLINE]
Singh RP, Agarwal R.
Prostate cancer prevention by silibinin.
Curr Cancer Drug Targets. 2004 Feb;4(1):1-11. Review.
PMID: 14965263 [PubMed - indexed for MEDLINE]
Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA.
Zyflamend((R))-Mediated Inhibition of Human Prostate Cancer PC3 Cell Proliferation: Effects on 12-LOX and Rb Protein Phosphorylation.
Cancer Biol Ther. 2007 Feb 25;6(2) [Epub ahead of pr
ScienceDaily (Feb. 8, 2006) - Vitamin D can inhibit the spread of prostate cancer cells by limiting the activity of two specific enzymes, University of Rochester Medical Center scientists report. \n\nThe finding means that vitamin D could provide beneficial treatment to prostate cancer patients with high levels of the enzymes, the scientists said.\n
The in vitro study, reported in the journal Carcinogenesis (Vol. 27, pp. 32-42), showed that vitamin D, in the form of the highly active 1alpha, 25-dihydroxyvitamin D3 (1,25-VD), inhibited the function of protease enzymes that are involved in tumour invasion.
"We found that 1,25-VD decreased matric metalloproteinases (MMP-9) and cathepsins (CPs), while it [also] increased the activity of their counterparts, tissue inhibitors of metalloproteinase-1 (TIMP-1) and cathepsin inhibitors," wrote lead author Bo-Ying Bao from the University of Rochester and Taipei Medical University.
"Mechanistic studies showed that 1,25-VD did not suppress MMP-9 expression at the transcriptional level, but reduced its mRNA stability," said Bao.
For the first time, medical groups have issued guidelines that say healthy older men should consider taking a drug that may reduce their risk of developing prostate cancer, even if they're just among the worried well who go in for regular screenings.\n\nThe drug, finasteride, is already used to treat male pattern baldness and to shrink enlarged prostates. The new guidelines suggest that patients who are already taking finasteride for those conditions or who go for regular prostate cancer screening tests should discuss long-term treatment with the drug with their doctors.
Blueberry Punch is an Australian product but is available for sale on the internet at £16 a bottle.\n\nIt also includes a host of other natural ingredients thought to boost health, including green tea, olive leaves, the herb tarragon and the spices turmeric and ginger.\n\nIt is thought the ingredients act together to cut inflammation and block a cancer gene.\n\nDr Jas Singh, who conducted the research on mice at Sydney University, said: "We have undertaken efficacy studies on individual components of Blueberry Punch in the same laboratory setting and found these effective in suppressing cell growth in culture.\n\n"We reasoned that synergistic or additive effects are likely to be achieved when they are combined."\n\nThe researchers looked at the effect of Blueberry Punch on both cancer cell cultures in the laboratory and genetically engineered mice with human prostate tumours. After only two weeks of having the syrupy solution added to their drinking water, their tumours had shrunk by
Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.
Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ.
Prostate. 2008 Aug 1;68(11):1223-31.
PMID: 18465755
DOI: 10.1002/pros.20788
Low doses of the active form of vitamin D and non-steroidal anti-inflammatory drugs act as a powerful combination to halt the growth of prostate cancer cells, say US scientists.
Writing in Cancer Research, a team from Stanford University says it discovered that the amount of both activated vitamin D, or calcitriol, and NSAIDs could be reduced by half to one-tenth the dosage to thwart prostate cancer cell growth in cell lines and primary tissue culture
This web site is dedicated to vitamin D and cancer. This is because exciting new research indicates that vitamin D-whether produced in the skin as a result of exposure to ultraviolet radiation (from sunlight or sun lamps) or obtained from supplementation with cholecalciferol (vitamin D3)-may help cancer patients. However, the research is far from complete.
Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg).\nNimptsch K, Rohrmann S, Linseisen J.\nAm J Clin Nutr. 2008 Apr;87(4):985-92.\nPMID: 18400723